You are here: Home Directory Faculty Frederick A.Luzzio

Frederick A.Luzzio

Professor

Frederick A.Luzzio
Division: Organic Chemistry
Specialty: Organic and Medicinal Chemistry
Phone: 502-852-7323
Email: faluzz01@louisville.edu
Website: Brown Cancer Center page

Education and Research Experience

1976 B.S.   Vanderbilt University
1979 M.S.  Tufts University
1982 Ph.D. Tufts University
1982-1985 Harvard University, Postdoctoral Fellow
 

Research Interests

Our current research interests involve the synthetic organic and medicinal chemistry of experimental cancer therapeutics. The investigations involve the multistep syntheses of core pharmacophores, the synthesis of a range of analogues or metabolites and their effect on and disposition in the biological test system. These projects are parts of larger projects, conducted in collaboration with the National Cancer Institute, which focus on the elucidation of the molecular target or the mode of action of the compounds as well as the design of analogues possessing a higher activity or selectivity. Compounds such as TNP-470 and thalidomide are potent angiogenesis inhibitors and synthetic studies are currently underway which identify chemical analogues of these compounds as well as newer and more efficient asymmetric routes to their core structures. The binding of the ansa macrocycle geldanamycin and the benzo-fused lactone radicicol to the chaperone heat shock protein (HSP-90) is of mechanistic importance. The interaction of these types of compounds with the target HSP-90 leads to inhibition of ATPase activity and cell cycle disruption, therefore the design and multistep synthesis of analogues are of interest in our laboratory.

Publications (recent or significant)

Synthetically-Useful Bronsted Acid-Promoted Arylbenzyl Ether o-Benzyphenol Rearrangements
F. A. Luzzio* and J. Chen
J. Org. Chem. 2009, 74, 5629-5632
 
Preparation of Benzoheterocyclic Carbaldehydes
F. A. Luzzio* and M. T. Wlodarczyk
Tetrahedron Lett. 2009, 50, 580-583.

Efficient Preparation and Processing of the 4-Methoxybenzyl (PMB) Group for Phenolic Protection Using Ultrasound
F. A. Luzzio* and J. Chen
J. Org. Chem. 2008, 73, 5621-5624

Ethyl-(Z)-2,3-difluoro-3-(tributylstannyl)acrylate; Ethyl-(E)-2,3-difluoro-3-(tributylstannyl)acrylate
F. A. Luzzio
Encyclopedia of Reagents for Organic Synthesis; e-Eros;
Paquette, L. A. Ed., John Wiley and Sons, Ltd.; Chichester, 2008

Preparation of b-Phenylnitroethanes having Electron-Donating Aryl Substitution
F. A. Luzzio*, M. T. Wlodarczyk, D. Y. Duveau, J. Chen
Tetrahedron Lett., 2007, 48, 6704-6708

Pyridinium Chlorochromate
F. A. Luzzio
Encyclopedia of Reagents for Organic Synthesis; e-EROS; Paquette, L. A. Ed., John Wiley and Sons, Ltd.: Chichester, 2007

A Chiral Pool Approach Toward the Synthesis of Thalidomide Metabolites
F. A. Luzzio*, D. Y. Duveau and W. D. Figg
Heterocycles, 2006, 70, 321-334

The Radical-Induced Cyclopentannulation of Henry (Nitroaldol)-Derived Intermediates
F. A. Luzzio*, J. P. Ott and D. Y. Duveau
J. Org. Chem. 2006 71, 5027-5030

Synthesis of Racemic 5-Hydroxy-3-Phthalimidoglutarimide. A Metabolite of Thalidomide Isolated from Human Plasma
F. A. Luzzio*, D. Y. Duveau, E. R. Lepper and W. D. Figg
J. Org. Chem. 2005, 70, 10117-10120

Triacylamines, Imides (Diacylamines), and Related Compounds
F. A. Luzzio
Science of Synthesis, Houben-Weyl Methods of Molecular Transformations, Weinreb, S., Ed.; Georg Thieme Verlag: Stuttgart, 2005, pp 259-324

Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) of Thalidomide Analogs as Angiogenesis Inhibitors
E. R. Lepper*, S. S. W. Ng, M. Gutschow, M. Weiss, T. K. Hecker, F. A. Luzzio, K. Eger and W. D. Figg
J. Med. Chem. 2004, 47, 2219-2227

Thalidomide Analogues: Derivatives of an Orphan Drug with Diverse Biological Activity
F. A. Luzzio* and W. D. Figg
Expert Opin. Ther. Patents 2004, 14(2) 215-229

Thalidomide Metabolites and Analogs. Synthesis and Antiangiogenic Activity of the Teratogenic and TNF-Modulatory Thalidomide Analog 2-(2,6-Dioxopiperidine-3-yl) Phthalimidine
F. A. Luzzio*; A. V. Mayorov; S. S. W. Ng; E. A. Kruger and W. D. Figg
J. Med. Chem. 2003, 46, 3793-3799

Antiangiogenic Activity of N-Substituted and Tetrafluorinated Thalidomide Analogues
S. S. W. Ng*, M. Gutschow, M. Weiss, S. Hauschildt, U. Teubert, T. K. Hecker, F. A. Luzzio, E. A. Kruger, K. Eger and W. D. Figg
Cancer Research 2003, 63, 3189-3194

Palladium (0)-Mediated Preparation of trans-4-Substituted-1-(Phthalimido)-2-Cyclopentenes
F. A. Luzzio* and A. V. Mayorov
Synlett, 2003, 4, 532-536.

Enzymatic Resolution of the 1,3,3-Trimethyl-2-Oxabicyclo[2.2.2] Octane (1,8-Cineole) System
F. A. Luzzio* and D. Y. Duveau
Tetrahedron: Asymmetry, 2002, 13, 1173-1180

The Henry Reaction: Recent Examples
F. A. Luzzio
Tetrahedron, 2001, 57, 915-945

A Rearrangement Route to Fenvaleric Acid
F. A. Luzzio* and R. W. Fitch
J. Prakt. Chem., 2000, 342 (5), 498-501

Thalidomide metabolites and analogs. Part II. Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine
F. A. Luzzio*, E. M. Thomas and W. D. Figg
Tetrahedron Lett. 2000, 41, 7151-7155

Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-γ-hydroxyglutamic acid
F. A. Luzzio*, A. V. Mayorov and W. D. Figg
Tetrahedron Lett., 2000, 41, 2275-2278
 
Document Actions
« November 2009 »
November
MoTuWeThFrSaSu
1
2345678
9101112131415
16171819202122
23242526272829
30